Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 02-Jul-24 7:30 AM View:  | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 28-Jun-24 | Option Exercise | 30,000 | $2.87 | $86,100.00 | 5% 643.12K to 673.12K | |
| 15-May-24 5:30 PM View: | Ashe Andrew D. See Remarks | Verve Therapeutics, Inc. (VERV) | 14-May-24 | Private Purchase | 76,000 | $6.26 | $475,760.00 | 29% 266.51K to 342.51K | |
| 03-Apr-24 5:00 PM View: | Nickerson Joan Chief Administrative Officer | Verve Therapeutics, Inc. (VERV) | 02-Apr-24 | Option Sale | 1,514 | $8.24 | $12,475.40 | (15%) 10.17K to 8.66K | |
| 03-Apr-24 5:00 PM View: | Nickerson Joan Chief Administrative Officer | Verve Therapeutics, Inc. (VERV) | 01-Apr-24 | Option Exercise | 3,315 | -- | -- | 48% 6.86K to 10.17K | |
| 05-Dec-23 4:30 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 01-Dec-23 | Private Purchase | 1,800,000 | $10.00 | $18,000,000.00 | 17% 10.37M to 12.17M | |
| 01-Dec-23 4:30 PM View: | Dorval Allison Chief Financial Officer | Verve Therapeutics, Inc. (VERV) | 29-Nov-23 | Option Sale | 554 | $11.45 | $6,343.30 | (12%) 4.61K to 4.06K | |
| 01-Dec-23 4:30 PM View: | Dorval Allison Chief Financial Officer | Verve Therapeutics, Inc. (VERV) | 29-Nov-23 | Option Exercise | 1,875 | -- | -- | 68% 2.74K to 4.61K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 18-Sep-23 | Gift | 37,168 | -- | -- | (8%) 465.49K to 428.33K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 18-Sep-23 | Gift | 37,168 | -- | -- | 9% 428.33K to 465.49K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 11-Aug-23 | Gift | 266,258 | -- | -- | 62% 428.33K to 694.58K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 11-Aug-23 | Gift | 266,258 | -- | -- | (38%) 694.58K to 428.33K | |
| 16-Dec-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 14-Dec-22 | Option Exercise | 36,000 | $2.87 | $103,320.00 | 543% 6.63K to 42.63K | |
| 02-Dec-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 01-Dec-22 | Sale | 865 | $22.95 | $19,851.80 | (12%) 7.49K to 6.63K | |
| 01-Dec-22 5:00 PM View: | Dorval Allison Chief Financial Officer | Verve Therapeutics, Inc. (VERV) | 29-Nov-22 | Option Exercise | 1,875 | -- | -- | 217% 0.86K to 2.74K | |
| 01-Dec-22 5:00 PM View: | Dorval Allison Chief Financial Officer | Verve Therapeutics, Inc. (VERV) | 29-Nov-22 | Option Sale | 554 | $22.10 | $12,243.40 | (20%) 2.74K to 2.19K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 07-Nov-22 | Gift | 106,200 | -- | -- | 25% 428.33K to 534.53K | |
| 09-Feb-24 10:00 PM View: | Adelman Burt A Director | Verve Therapeutics, Inc. (VERV) | 07-Nov-22 | Gift | 106,200 | -- | -- | (20%) 534.53K to 428.33K | |
| 08-Nov-22 5:51 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 04-Nov-22 | Sale (Planned) | 48,583 | $31.14 | $1,512,810.00 | (< 1%) 10.42M to 10.37M | |
| 08-Nov-22 5:04 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 04-Nov-22 | Sale (Planned) | 97,166 | $31.14 | $3,025,610.00 | (< 1%) 10.47M to 10.37M | |
| 08-Nov-22 5:51 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 04-Nov-22 | Disposition (other) Duplicate | 48,583 | -- | -- | (< 1%) 10.47M to 10.42M | |
| 08-Nov-22 5:04 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 04-Nov-22 | Disposition (other) | 48,583 | -- | -- | (< 1%) 10.51M to 10.47M | |
| 04-Nov-22 5:58 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 03-Nov-22 | Disposition (other) Duplicate | 49,569 | -- | -- | (< 1%) 10.56M to 10.52M | |
| 04-Nov-22 4:16 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 03-Nov-22 | Disposition (other) | 49,569 | -- | -- | (< 1%) 10.61M to 10.56M | |
| 04-Nov-22 5:58 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 03-Nov-22 | Sale (Planned) | 49,568 | $32.79 | $1,625,500.00 | (< 1%) 10.52M to 10.47M | |
| 04-Nov-22 4:16 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 03-Nov-22 | Sale (Planned) | 99,137 | $32.79 | $3,251,030.00 | (< 1%) 10.56M to 10.47M | |
| 04-Nov-22 5:58 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 02-Nov-22 | Sale (Planned) | 28,652 | $35.94 | $1,029,830.00 | (< 1%) 10.59M to 10.56M | |
| 04-Nov-22 4:16 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 02-Nov-22 | Sale (Planned) | 57,303 | $35.94 | $2,059,630.00 | (< 1%) 10.62M to 10.56M | |
| 04-Nov-22 5:58 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 02-Nov-22 | Disposition (other) Duplicate | 28,651 | -- | -- | (< 1%) 10.62M to 10.59M | |
| 04-Nov-22 4:16 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 02-Nov-22 | Disposition (other) | 28,651 | -- | -- | (< 1%) 10.65M to 10.62M | |
| 02-Nov-22 9:02 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 01-Nov-22 | Sale (Planned) | 31,963 | $36.79 | $1,175,850.00 | (< 1%) 10.65M to 10.62M | |
| 02-Nov-22 4:25 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 01-Nov-22 | Sale (Planned) | 63,926 | $36.79 | $2,351,710.00 | (< 1%) 10.69M to 10.62M | |
| 02-Nov-22 9:02 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 01-Nov-22 | Disposition (other) Duplicate | 31,963 | -- | -- | (< 1%) 10.69M to 10.65M | |
| 02-Nov-22 4:25 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 01-Nov-22 | Disposition (other) | 31,963 | -- | -- | (< 1%) 10.72M to 10.69M | |
| 02-Nov-22 9:02 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 31-Oct-22 | Disposition (other) Duplicate | 53,697 | -- | -- | (< 1%) 10.79M to 10.74M | |
| 02-Nov-22 4:25 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 31-Oct-22 | Disposition (other) | 53,697 | -- | -- | (< 1%) 10.85M to 10.79M | |
| 02-Nov-22 9:02 PM View: | Yeshwant Krishna Director 10% Owner | Verve Therapeutics, Inc. (VERV) | 31-Oct-22 | Sale (Planned) | 53,696 | $38.64 | $2,074,640.00 | (< 1%) 10.74M to 10.69M | |
| 02-Nov-22 4:25 PM View: | Gv 2017 Gp, L.L.C. | Verve Therapeutics, Inc. (VERV) | 31-Oct-22 | Sale (Planned) | 107,393 | $38.64 | $4,149,330.00 | (< 1%) 10.79M to 10.69M | |
| 01-Nov-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 28-Oct-22 | Planned Option Sale | 10,000 | $39.90 | $399,000.00 | (60%) 16.63K to 6.63K | |
| 01-Nov-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 28-Oct-22 | Option Exercise | 10,000 | $1.48 | $14,800.00 | 151% 6.63K to 16.63K | |
| 05-Oct-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 03-Oct-22 | Planned Option Sale | 50,000 | $33.65 | $1,682,620.00 | (7%) 689.83K to 639.83K | |
| 05-Oct-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 03-Oct-22 | Option Exercise | 50,000 | $1.39 | $69,500.00 | 8% 639.83K to 689.83K | |
| 27-Sep-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 23-Sep-22 | Option Exercise | 60,000 | $1.48 | $88,800.00 | 905% 6.63K to 66.63K | |
| 27-Sep-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 23-Sep-22 | Planned Option Sale | 60,000 | $35.34 | $2,120,390.00 | (90%) 66.63K to 6.63K | |
| 29-Aug-22 5:00 PM View: | Ashe Andrew D. See Remarks | Verve Therapeutics, Inc. (VERV) | 25-Aug-22 | Option Exercise | 95,787 | $1.59 | $152,217.00 | 56% 170.72K to 266.51K | |
| 11-Aug-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 10-Aug-22 | Option Exercise | 50,000 | $1.39 | $69,500.00 | 8% 639.83K to 689.83K | |
| 11-Aug-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 10-Aug-22 | Planned Option Sale | 50,000 | $29.90 | $1,495,000.00 | (7%) 689.83K to 639.83K | |
| 22-Jul-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 20-Jul-22 | Option Exercise | 20,000 | $1.39 | $27,800.00 | 302% 6.63K to 26.63K | |
| 22-Jul-22 5:00 PM View: | Bellinger Andrew CSO & CMO | Verve Therapeutics, Inc. (VERV) | 20-Jul-22 | Planned Option Sale | 20,000 | $34.90 | $698,000.00 | (75%) 26.63K to 6.63K | |
| 21-Jul-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 19-Jul-22 | Option Exercise | 50,000 | $1.39 | $69,500.00 | 8% 639.83K to 689.83K | |
| 21-Jul-22 5:00 PM View: | Kathiresan Sekar Chief Executive Officer Director | Verve Therapeutics, Inc. (VERV) | 19-Jul-22 | Planned Option Sale | 50,000 | $29.90 | $1,495,000.00 | (7%) 689.83K to 639.83K |
